Welcome to the e-CCO Library!

P062: Antibody responses to SARS-CoV-2 vaccination outperform responses induced by natural infection in patients with IBD receiving immunosuppressive medications: a report from the ICARUS-IBD consortium.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: González Cueto, E.(1)*;Matthew, E.(1);Wellens, J.(2,3);Martinez Pazos, V.(4);Thompson, C.(5);Klenerman, P.(1,3);Cadwell, K.(6);Colombel, J.F.(4);Satsangi, J.(3);Wong, S.Y.(4);
Created: Friday, 14 July 2023, 10:48 AM
P062: Critical role of the IL-33/ST2 axis in colitis-associated colorectal cancer
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. R. Lopetuso*1, 2, 3, C. De Salvo3, L. Di Martino3, W. Goodman3, F. Scaldaferri2, A. Gasbarrini2, T. T. Pizarro3

Created: Friday, 22 February 2019, 9:49 AM
P062: Differences in immune cell population subsets in inflammatory bowel disease patients under anti-TNF treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Notararigo*1,2, J. E. Viñuela Roldán3, M. Abanades-Tercero4, J. E. Dominguez-Munoz1, M. Barreiro-de Acosta1

Created: Friday, 22 February 2019, 9:41 AM
P062: Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Alsoud, D.(1);Verstockt, S.(1);Sabino, J.(1,2);Ferrante, M.(1,2);Noor, N.(3,4);Verstockt, B.(1,2);Vermeire, S.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P062: Small intestinal lactulose and sucralose hyper-permeability in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A.K. Al-Saffar1,2, A.H. Md.1, G. Hall1, P. Hellström1, D.-L. Webb1*

Created: Thursday, 21 February 2019, 9:14 AM
P062: The narrow spectrum kinase inhibitor TOP1288 demonstrates potent anti-inflammatory effects in a T cell adoptive transfer colitis model through a topical mode of action
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Solanke Y., Foster M., Fyfe M., Rowley A., Sirohi S., Webber S., Walshe C.

Created: Wednesday, 20 February 2019, 10:36 AM
P063 B-cell receptor signalling in lymphoid tissues may be regulated by CEACAM1
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Nagaishi, N. Tsugawa, D. Yamada, T. Watabe, M. Onizawa, M. Watanabe

Created: Thursday, 30 January 2020, 10:12 AM
P0630: Are women with inflammatory bowel disease at risk of abnormal cervix cytology? -results of retrospective study
Year: 2025
Source: ECCO'25
Authors: Tulewicz-Martix7x7x7 E.(1)*;Lewandowskix7x7x7 K.(2);Karłowiczx7x7x7 K.(2);Maciejewskax7x7x7 K.(2);Sierakowskax7x7x7 I.(2);Szwedax7x7x7 H.(3);Rydzewskax7x7x7 G.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0631: Short-term effectiveness of risankizumab in patients with Crohn´s Disease: Experience in our centre
Year: 2025
Source: ECCO'25
Authors: Valdés Delgadox7x7x7 T.(1);Rodríguez Gallardox7x7x7 M.(1)*;Maldonado Pérezx7x7x7 B.(1);Belvis Jiménezx7x7x7 M.(1);Castro Lariax7x7x7 L.(1); Argüelles Ariasx7x7x7 F.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0632: Analysis of serological responses to SARS-Cov-2 vaccination in patients with Inflammatory Bowel Disease in India identifies low BMI as an independent determinant of vaccine non-response
Year: 2025
Source: ECCO'25
Authors: Wongx7x7x7 S.Y.(1)*;Moranx7x7x7 H.R.(1);Elgood-Huntx7x7x7 G.(2);Stollex7x7x7 L.(3);Giselbrechtx7x7x7 E.(1);Wellensx7x7x7 J.(4);Ahujax7x7x7 V.(5);Virmanix7x7x7 S.(5);Kediax7x7x7 S.(5);Duttax7x7x7 U.(6);Sinhax7x7x7 S.K.(6);Sharmax7x7x7 V.(6);Samantax7x7x7 J.(6);Shahx7x7x7 J.(6);Singhx7x7x7 A.K.(6);Kaurx7x7x7 H.(7);Colombelx7x7x7 J.F.(1);Thompsonx7x7x7 C.(8);Satsangix7x7x7 J.(9);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0633: Real World Outcomes of Upadacitinib Induction Therapy for Patient with Inflammatory Bowel Disease in Korea
Year: 2025
Source: ECCO'25
Authors: Yex7x7x7 B.D.(1)*;Kimx7x7x7 M.K.(2);Hongx7x7x7 S.W.(2);Hwangx7x7x7 S.W.(1);Parkx7x7x7 S.H.(1);Yangx7x7x7 D.H.(2);Byeonx7x7x7 J.S.(2);Myungx7x7x7 S.J.(2);Yangx7x7x7 S.K.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0634: Upadacitinib Effectiveness And Safety In Patients With Ulcerative Colitis: Data From A Real-World Study
Year: 2025
Source: ECCO'25
Authors: MocciMD FRCPx7x7x7 G.(1)*;Scaldaferrix7x7x7 F.(2);Napoltitanox7x7x7 D.(2);Pugliesex7x7x7 D.(2);Maconix7x7x7 G.(3);Picax7x7x7 R.(4);Savarinox7x7x7 E.(5);Costax7x7x7 F.(6);Ceccarellix7x7x7 L.(6);Marzox7x7x7 M.(7);Eliseix7x7x7 W.(8);Lombardix7x7x7 G.(9);Ribaldonex7x7x7 D.G.(10);Bertanix7x7x7 L.(11);Rodinox7x7x7 S.(12);Orrùx7x7x7 G.(13);Bodinix7x7x7 G.(14);Pranzox7x7x7 G.(15);Scarcellix7x7x7 A.(16);Luppinox7x7x7 I.(17);Ferronatox7x7x7 A.(18);Spagnuolox7x7x7 R.(19);Gravinax7x7x7 A.G.(20);Pellegrinox7x7x7 R.(21);Vesperex7x7x7 G.(22);Allegrettax7x7x7 L.(23);Fanigliuolox7x7x7 L.(24);Grossix7x7x7 L.(25);Cortellinix7x7x7 F.(26);Piergallinix7x7x7 S.(27);Caponex7x7x7 P.(28);Gaianix7x7x7 F.(29);Mucherinox7x7x7 C.(30);D'Ascolix7x7x7 B.(31);Coluccix7x7x7 R.(32);Onidix7x7x7 F.M.(1);Usai Sattax7x7x7 P.(33);Picchiox7x7x7 M.(34);Papax7x7x7 A.(35);Tursix7x7x7 A.(36);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0635: Degree of interest in using a cognitive-behavioral therapy application for fatigue management and related factors among outpatients with inflammatory bowel disease
Year: 2025
Source: ECCO'25
Authors: Tanakax7x7x7 M.(1)*;Kawakamix7x7x7 A.(1);Wakaix7x7x7 S.(1);Takaix7x7x7 M.(2);Sakagamix7x7x7 K.(3);Itox7x7x7 H.(3);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0636: Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study
Year: 2025
Source: ECCO'25
Authors: Magrox7x7x7 F.(1)*;Peyrin-Birouletx7x7x7 L.(2);Biedermannx7x7x7 L.(3);Sandsx7x7x7 B.E.(4);Danesex7x7x7 S.(5);Dulaix7x7x7 P.S.(6);Dubinskyx7x7x7 M.(7);Tilgx7x7x7 H.(8);Siegmundx7x7x7 B.(9);Hisamatsux7x7x7 T.(10);Shanx7x7x7 K.(11);Jacobsteinx7x7x7 D.(12);Cataldix7x7x7 F.(13);Rabbatx7x7x7 C.(13);Vermeirex7x7x7 S.(14);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0637: Ebrasodebart (Ent001) First in Human trial in healthy volunteers: pharmacokinetic results and predicted therapeutic concentrations to preserve mucosal healing in patients with Ulcerative Colitis
Year: 2025
Source: ECCO'25
Authors: Zangarinix7x7x7 M.(1)*;Marinx7x7x7 V.(1);Mauccix7x7x7 R.(1);Stabilex7x7x7 M.(1);Di Sanzax7x7x7 C.(1);Maestronix7x7x7 A.(2);Amabilex7x7x7 G.(1);Nardinix7x7x7 C.(1);D'Addiox7x7x7 F.(2);Fiorinax7x7x7 P.(2);Olsonx7x7x7 L.M.(1);Canduccix7x7x7 F.(1);Porziox7x7x7 S.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0638: Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study
Year: 2025
Source: ECCO'25
Authors: Sandsx7x7x7 B.E.(1)*;Colombelx7x7x7 J.F.(1);Rubinx7x7x7 D.T.(2);Schreiberx7x7x7 S.(3);Siegelx7x7x7 C.A.(4);Yarurx7x7x7 A.(5);Danesex7x7x7 S.(6);Kangx7x7x7 A.(7);Kimx7x7x7 D.H.(7);Leex7x7x7 Y.N.(7);Hanauerx7x7x7 S.B.(8);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0639: Population pharmacokinetics of subcutaneous vedolizumab in Crohn’s disease and Ulcerative Colitis
Year: 2025
Source: ECCO'25
Authors: Vremanx7x7x7 N.(1)*;Anjiex7x7x7 S.I.(2);Gecsex7x7x7 K.B.(2);Lowenbergx7x7x7 M.(2);D'Haensx7x7x7 G.R.A.M.(2);Mathôtx7x7x7 R.A.A.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P063: Dissecting the role of rage in intestinal fibrosis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Speca*1, M. Body-Malapel1, C. Fradin1, M. Djouina1, E. Boulanger1, A.-M. Schmidt2, P. Desreumaux1, C. Vignal1

Created: Friday, 22 February 2019, 9:49 AM
P063: Expression of the coinhibitory receptor TIGIT on memory CD4+ T cells is induced by TCR ligation and retinoic acid co-stimulation and is elicited during microbial colonization of the intestine.
Year: 2022
Source: ECCO'22
Authors: Barendregt, D.(1);Joosse, M.E.(1);van Berkel, L.A.(1);van Schoonhoven, A.(1);Samsom, J.N.(1);
Created: Friday, 11 February 2022, 3:52 PM
P063: Faecal calprotectin as a non-invasive treatment target to predict mucosal healing and histological remission in asymptomatic ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Correia Varela Almeida1*, J.M. Vázquez Morón1, E. Gómez Delgado1, H. Pallarés Manrique1, A. Talavera Fabuel2, A. Bejarano García1

Created: Thursday, 21 February 2019, 9:14 AM